Our Pricing

How to Switch From Mounjaro to Wegovy: UK Clinical Guidance

Many patients consider whether to switch from Mounjaro to Wegovy when managing their weight loss journey, often due to supply availability, cost considerations, or individual response to treatment. Both medications belong to the GLP-1 receptor agonist class but contain different active ingredients—tirzepatide in Mounjaro and semaglutide in Wegovy—each with distinct dosing schedules and clinical profiles. Understanding the transition process, dose equivalence, and what to expect during the switch is essential for maintaining safe and effective weight management under UK prescriber supervision.

Why Patients Switch From Mounjaro to Wegovy in the UK

The decision to switch from Mounjaro to Wegovy typically arises from several practical and clinical factors. Supply chain disruptions have periodically affected both medications across UK pharmacies, prompting patients and prescribers to consider alternatives to maintain continuity of care. Cost differences also play a significant role—whilst Mounjaro is priced from £124.99 at Cured Pharmacy, Wegovy starts from £124.99, yet individual insurance coverage or personal budgets may favour one over the other depending on specific circumstances[1].

Clinical response varies between individuals, and some patients find that switching from Mounjaro to Wegovy better suits their tolerance profile or weight loss trajectory. Mounjaro's dual GIP/GLP-1 receptor agonism produced an average weight reduction of 15-22.5% in the SURPASS-1 trial, whilst Wegovy's semaglutide achieved 14.9% average weight loss in the STEP 1 trial[2]. Prescribers may recommend a switch if side effects prove more manageable on one medication, or if plateau effects suggest benefit from changing the therapeutic mechanism. All switches require clinical assessment by a UK-registered prescriber to ensure safety and appropriateness for the individual patient.

Dose Equivalence When You Switch From Mounjaro to Wegovy

Understanding dose equivalence is critical when planning to switch from Mounjaro to Wegovy, as the two medications follow different titration schedules and mg-for-mg dosing is not directly comparable. Mounjaro uses a four-week escalation starting at 2.5mg weekly, increasing through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum maintenance dose of 15mg. Wegovy begins at 0.25mg weekly, doubling every four weeks through 0.5mg, 1mg, 1.7mg, to a maintenance dose of 2.4mg[3].

UK prescribers typically assess the patient's current Mounjaro dose and weight loss response to determine the appropriate Wegovy starting point. A patient stable on Mounjaro 5mg may transition to Wegovy 1mg or 1.7mg depending on tolerability and efficacy observed during their tirzepatide treatment. There is no universally agreed conversion chart, as individual response, side effect history, and clinical goals guide the decision. The switch from Mounjaro to Wegovy should involve a brief washout period or direct crossover as determined by the prescriber, with close monitoring during the first four weeks to assess gastrointestinal tolerance and glycaemic effects where relevant.

Recommended Transition Protocol

Most UK clinicians recommend administering the first Wegovy dose one week after the final Mounjaro injection to allow clearance of tirzepatide, which has a half-life of approximately five days. Starting Wegovy at a lower dose than the equivalent Mounjaro strength reduces the risk of overlapping GLP-1 effects and minimises nausea or gastrointestinal discomfort. Patients should report any significant side effects or lack of appetite control during the transition, as dose adjustments may be required to optimise outcomes when switching from Mounjaro to Wegovy.

What to Expect During the Switch From Mounjaro to Wegovy

Patients switching from Mounjaro to Wegovy commonly experience a brief adjustment period as the body adapts to the new medication's pharmacokinetics and receptor activity profile. Gastrointestinal side effects—nausea, constipation, diarrhoea—may re-emerge or change in intensity, even if previously well-tolerated on Mounjaro. Semaglutide's longer half-life (approximately seven days) means steady-state concentrations build gradually, and full appetite suppression may take two to three weeks to match prior Mounjaro effects[4].

Weight loss trajectory may plateau temporarily during the switch from Mounjaro to Wegovy as the body recalibrates to the different GLP-1 agonist. Clinical experience shows most patients resume consistent weight reduction within four to six weeks, provided adherence to the prescribed dose schedule and lifestyle modifications continue. Blood glucose levels in patients with type 2 diabetes should be monitored closely during the transition, as the shift from dual GIP/GLP-1 agonism to pure GLP-1 agonism can subtly alter glycaemic control. UK prescribers at Cured Pharmacy provide ongoing support throughout the switching process, with follow-up consultations available to address any concerns or adjust dosing as clinically indicated.

Managing Side Effects During Transition

To minimise side effects when you switch from Mounjaro to Wegovy, maintain consistent injection timing, stay well-hydrated, and eat smaller, more frequent meals rich in fibre. Avoid high-fat foods during the first fortnight, as these can exacerbate nausea. If gastrointestinal symptoms persist beyond two weeks or significantly impact daily function, contact your prescriber—dose titration speed may need adjustment, or additional symptomatic management may be appropriate.

Cost Comparison: Switch From Mounjaro to Wegovy at Cured Pharmacy

Pricing considerations often influence the decision to switch from Mounjaro to Wegovy, particularly for patients funding treatment privately in the UK. At Cured Pharmacy, Mounjaro is available from £20 offering the most competitive tirzepatide pricing in the UK market. Wegovy starts from £124.99, reflecting the higher cost of semaglutide supply chains. Patients can Save £20 off their first order using code Weightlossnew, reducing the initial financial barrier when transitioning between medications.

Transparent upfront pricing at Cured Pharmacy ensures patients know the exact cost before completing their clinical consultation, with no hidden fees or subscription lock-ins. All doses from 0.25mg to 2.4mg for Wegovy, and 2.5mg to 15mg for Mounjaro, are available subject to prescriber approval following a free online assessment. Next-day delivery in discreet packaging is standard, ensuring continuity of treatment when switching from Mounjaro to Wegovy without interruption to your weight management programme.

Clinical Efficacy: Switch From Mounjaro to Wegovy Outcomes

Clinical trial data demonstrate robust efficacy for both medications, though head-to-head comparisons remain limited. The SURPASS-2 trial showed tirzepatide (Mounjaro) achieved superior weight loss compared to semaglutide 1mg in patients with type 2 diabetes, with 15mg tirzepatide producing 11.2kg average reduction versus 5.7kg for semaglutide[5]. However, Wegovy uses a higher 2.4mg semaglutide dose than studied in SURPASS-2, and the STEP trials showed this strength delivered 14.9% mean body weight reduction in adults without diabetes[2].

When patients switch from Mounjaro to Wegovy, the overall weight loss trajectory typically continues, though individual response varies. Some patients report equivalent or improved results on Wegovy, particularly if Mounjaro caused intolerable side effects that limited dose escalation. Others may experience a modest reduction in efficacy, especially if switching from higher Mounjaro doses (12.5mg or 15mg) to Wegovy 2.4mg. UK prescribers evaluate each case individually, considering prior weight loss percentage, current BMI, comorbidities, and patient preference when guiding the switch from Mounjaro to Wegovy to optimise long-term outcomes.

Long-Term Weight Maintenance After Switching

Sustaining weight loss after you switch from Mounjaro to Wegovy requires ongoing medication adherence combined with dietary and physical activity modifications. Both medications work by reducing appetite and slowing gastric emptying, but neither produces permanent metabolic changes—discontinuation typically results in weight regain. UK clinical guidelines recommend indefinite treatment for obesity management, with regular prescriber review every three to six months to assess continued benefit and tolerability when switching from Mounjaro to Wegovy or maintaining either therapy long-term.

How to Switch From Mounjaro to Wegovy Through Cured Pharmacy

Cured Pharmacy streamlines the process to switch from Mounjaro to Wegovy with a straightforward online clinical pathway. Begin by completing the free medical consultation questionnaire, which takes under three minutes and covers your current Mounjaro dose, weight loss progress, side effects, and medical history. A UK-registered prescriber reviews your submission, typically within 24 hours, and determines the appropriate Wegovy starting dose based on your tirzepatide treatment history and clinical response.

Once approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (registration 9012511) under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073). Medication is dispatched via next-day delivery in 100% discreet packaging, with tracking provided. Ongoing prescriber support is included—if you experience any issues during the switch from Mounjaro to Wegovy, our clinical team is available via phone (+44 116 4646009) or secure messaging. Follow-up consultations ensure dose adjustments are made promptly to maintain safe, effective weight management throughout your transition and beyond.

Scientific References

1. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Wegovy 2.4mg solution for injection. MHRA UK. [accessed 15 August 2026]
4. Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in Endocrinology, 12, 645563. [accessed 15 August 2026]
5. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.